Mastermind Session: Building a Consensus on Model Selection Criteria Across in Vitro, 3D, in Vivo, Ex Vivo & in Silico Following the Recent FDA Roadmap to Safeguard Animal Welfare Practices
- Understanding the different tumour models used in drug discovery and development across the field
- Reiterating the importance of assessing animal welfare impact when selecting models, with strict parameters to ensure the science can be obtained without excessive animal burden
- Discussing how we can continue to incorporate the 3Rs into our workflows better